Mildronate (Meldonium Dihydrate)

Meldonium works by inhibiting the enzyme gamma‑butyrobetaine dioxygenase, which reduces the synthesis of carnitine. Lower carnitine levels shift cellular metabolism from fatty‑acid oxidation toward glucose oxidation, a pathway that consumes less oxygen. This metabolic shift enhances cardiac efficiency during limited oxygen supply and also provides antioxidant protection to heart cells.

The dosage of Mildronate is individualized and determined by the prescribing clinician based on the patient’s condition, weight, and response. It is administered as an intravenous infusion, and the exact amount, frequency, and duration should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for Meldonium during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant. Healthcare providers generally advise avoiding the drug in pregnant or nursing women unless no suitable alternatives exist.

To order Mildronate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and assist with any necessary import documentation.

Mildronate belongs to the class of metabolic modulators, similar to agents like trimetazidine. While both aim to improve myocardial efficiency, Meldonium primarily reduces carnitine synthesis, shifting metabolism toward glucose use, whereas trimetazidine inhibits fatty‑acid oxidation directly. Clinical choice depends on patient profile, tolerability, and physician preference.

Mildronate should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and avoid exposure to extreme temperatures. Follow standard aseptic techniques when preparing the solution for intravenous administration.

Mildronate is supplied as a sterile injectable solution for intravenous infusion. The preparation is added to an appropriate diluent and administered over a controlled period, as directed by the prescribing clinician. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy.

The most serious adverse events associated with Mildronate include severe allergic reactions such as anaphylaxis, marked hypotension, cardiac arrhythmias, and significant elevations in liver enzymes indicating hepatic injury. Patients should be monitored closely for these signs, and treatment should be discontinued if any serious reaction occurs.

Mildronate is contraindicated in individuals with known hypersensitivity to Meldonium or any excipients in the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless a specialist determines that benefits outweigh risks. Pregnant or breastfeeding women should use the drug only if absolutely necessary.